Skip to main content

Table 2 Change in serum lipids and lipoproteins with berberine ursodeoxycholate therap

From: Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia

Lipid

Time

Placebo

500 mg/day

P Value vs. placebo

1000 mg/day

ANOVA P Value vs. placebo

2000 mg/day

ANOVA P Value vs. placebo

Triglycerides

Baseline*

1.91

2.11

–

1.76

–

1.60

–

Day 14

1.84

1.89

n.s.

1.73

n.s.

1.42

n.s.

Day 28

2.58

2.27

n.s.

1.86

0.028

1.54

0.0018

Total Cholesterol

Baseline*

6.23

6.13

–

5.81

–

5.91

–

Day 14

6.39

5.96

n.s.

5.51

n.s.

5.37

0.01

Day 28

6.59

5.88

n.s.

5.54

n.s.

5.42

0.003

LDL Cholesterol

Baseline*

3.91

4.01

–

3.68

–

3.85

–

Day 14

4.05

3.87

n.s.

3.42

n.s.

3.40

0.0093

Day 28

3.85

3.72

n.s.

3.51

n.s.

3.44

0.091

Non-HDL Cholesterol

Baseline*

4.66

4.85

–

4.48

–

4.62

–

Day 14

4.90

4.75

n.s.

4.23

n.s.

4.04

0.0018

Day 28

5.18

4.71

0.03

4.31

0.025

4.14

0.0002

HDL Cholesterol

Baseline*

1.55

1.25

–

1.32

–

1.24

–

Day 14

1.49

1.22

n.s.

1.29

n.s.

1.33

n.s.

Day 28

1.42

1.17

n.s.

1.23

n.s.

1.29

n.s.

  1. *Baseline value is calculated from mean of Screening and Baseline visits
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X